**Supplementary materials**

**Search strings:**

Pubmed (1433) (((((("schizophrenia"[Title/Abstract]) OR ("schizophrenia spectrum and other psychotic disorders"[MeSH Terms])) OR ("psychosis"[Title/Abstract])) OR ("psychotic disorder"[Title/Abstract])) OR ("antipsychotic"[Title/Abstract])) AND (((((("mitochondria"[Title/Abstract]) OR (mitochondrion[Title/Abstract])) OR ("mitochondria"[MeSH Terms])) OR ("free radical"[Title/Abstract])) OR ("antioxidant"[Title/Abstract]))

Embase (1906) #1 AND #2

#2

mitochondria:ti,ab,kw OR mitochondrion:ti,ab,kw OR 'free radical':ti,ab,kw OR antioxidant:ti,ab,kw

#1

schizophrenia:ti,ab,kw OR psychosis:ti,ab,kw OR antipsychotic:ti,ab,kw OR 'psychotic disorder':ti,ab,kw

Scopus (3027)

( ( TITLE-ABS-KEY ( schizophrenia ) OR TITLE-ABS-KEY ( psychosis ) OR TITLE-ABS-KEY ( psychotic AND disorder ) OR TITLE-ABS-KEY ( antipsychotic ) ) ) AND ( ( TITLE-ABS-KEY ( mitochondria ) OR TITLE-ABS-KEY ( mitochondrion ) OR TITLE-ABS-KEY ( free AND radical ) OR TITLE-ABS-KEY ( antioxidant ) ) )

| Section and Topic | Item # | Checklist item | Location where item is reported |
|---|---|---|---|
| **TITLE** | | | |
| Title | 1 | Identify the report as a systematic review. | 1 |
| **ABSTRACT** | | | |
| Abstract | 2 | See the PRISMA 2020 for Abstracts checklist. | 1 |
| **INTRODUCTION** | | | |
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge. | 2 |
| Objectives | 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses. | 2-3 |
| **METHODS** | | | |
| Eligibility criteria | 5 | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. | 3 |
| Information sources | 6 | Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | 3 |
| Search strategy | 7 | Present the full search strategies for all databases, registers and websites, including any filters and limits used. | 3 |
| Selection process | 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. | 3 |
| Data collection process | 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. | 3 |
| Data items | 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. | 3 |
| | 10b | List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. | 3 |
| Study risk of bias assessment | 11 | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. | Not applicable |
| Effect measures | 12 | Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. | Not applicable |
| Synthesis methods | 13a | Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). | Not applicable |
| | 13b | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. | Not applicable |
| | 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | Not applicable |
| | 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | Not applicable |
| | 13e | Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). | Not |

| Section and Topic | Item # | Checklist item | Location where item is reported |
|---|---|---|---|
| | | | applicable |
| | 13f | Describe any sensitivity analyses conducted to assess robustness of the synthesized results. | Not applicable |
| Reporting bias assessment | 14 | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). | Not applicable |
| Certainty assessment | 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | Not applicable |
| **RESULTS** | | | |
| Study selection | 16a | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. | 4 |
| | 16b | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. | Not applicable |
| Study characteristics | 17 | Cite each included study and present its characteristics. | 4-28 |
| Risk of bias in studies | 18 | Present assessments of risk of bias for each included study. | Not applicable |
| Results of individual studies | 19 | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots. | Not applicable |
| Results of syntheses | 20a | For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. | Not applicable |
| | 20b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. | Not applicable |
| | 20c | Present results of all investigations of possible causes of heterogeneity among study results. | Not applicable |
| | 20d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. | Not applicable |
| Reporting biases | 21 | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. | Not applicable |
| Certainty of evidence | 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. | Not applicable |
| **DISCUSSION** | | | |
| Discussion | 23a | Provide a general interpretation of the results in the context of other evidence. | 29-30 |
| | 23b | Discuss any limitations of the evidence included in the review. | 29-30 |
| | 23c | Discuss any limitations of the review processes used. | Not applicable |

| Section and Topic | Item # | Checklist item | Location where item is reported |
|---|---|---|---|
| | 23d | Discuss implications of the results for practice, policy, and future research. | 29-30 |
| **OTHER INFORMATION** | | | |
| Registration and protocol | 24a | Provide registration information for the review, including register name and registration number, or state that the review was not registered. | 3 |
| | 24b | Indicate where the review protocol can be accessed, or state that a protocol was not prepared. | 3 |
| | 24c | Describe and explain any amendments to information provided at registration or in the protocol. | 3 |
| Support | 25 | Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. | 30 |
| Competing interests | 26 | Declare any competing interests of review authors. | 30 |
| Availability of data, code and other materials | 27 | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. | Not applicable |

## Prisma checklist

*From:* Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

**Supplementary Table S1.** Studies included in the systematic review.

| Author | Title | Study design |
|---|---|---|
| Abdalla, D. S.-//-Bechara, E. J. | The effect of chlorpromazine and Li2CO3 on the superoxide dismutase and glutathione peroxidase activities of rat brain, liver and erythrocytes | preclinical |
| Abdel-Salam, O. M.-//-El-Sayed El-Shamarka, M.-//-Salem, N. A.-//-El-Mosallamy, A. E.-//-Sleem, A. A. | Amelioration of the haloperidol-induced memory impairment and brain oxidative stress by cinnarizine | preclinical |
| Abou El-Magd, R. M.-//-Park, H. K.-//-Kawazoe, T.-//-Iwana, S.-//-Ono, K.-//-Chung, S. P.-//-Miyano, M.-//-Yorita, K.-//-Sakai, T.-//-Fukui, K. | The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia | preclinical |
| Adler, L. A.-//-Peselow, E.-//-Rotrosen, J.-//-Duncan, E.-//-Lee, M.-//-Rosenthal, M.-//-Angrist, B. | Vitamin E treatment of tardive dyskinesia | clinical |
| Adler, L. A.-//-Edson, R.-//-Lavori, P.-//-Peselow, E.-//-Duncan, E.-//-Rosenthal, M.-//-Rotrosen, J. | Long-term treatment effects of vitamin E for tardive dyskinesia | clinical |
| Afshari, P.-//-Yao, W. D.-//-Middleton, F. A. | Reduced Slc1a1 expression is associated with neuroinflammation and impaired sensorimotor gating and cognitive performance in mice: Implications for schizophrenia | preclinical |
| Akhondzadeh, S.-//-Safarcherati, A.-//-Amini, H. | Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial | clinical |
| Altar, C. A.-//-Jurata, L. W.-//-Charles, V.-//-Lemire, A.-//-Liu, P.-//-Bukhman, Y.-//-Young, T. A.-//-Bullard, J.-//-Yokoe, H.-//-Webster, M. J.-//-Knable, M. B.-//-Brockman, J. A. | Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts | preclinical |
| Amiri, S.-//-Jafari-Sabet, M.-//-Keyhanfar, F.-//-Falak, R.-//-Shabani, M.-//-Rezayof, A. | Hippocampal and prefrontal cortical NMDA receptors mediate the interactive effects of olanzapine and lithium in memory retention in rats: the involvement of CAMKII-CREB signaling pathways | preclinical |
| Andrade, C. | Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia | review |
| Andreazza, A. C.-//-Shao, L.-//-Wang, J. F.-//-Young, L. T. | Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder | preclinical |
| Ansari, Z.-//-Pawar, S.-//-Seetharaman, R. | Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing? | review |
| Antkiewicz-Michaluk, L.-//-Ossowska, K.-//-Romańska, I.-//-Michaluk, J.-//-Vetulani, J. | 3-Methoxytyramine, an extraneuronal dopamine metabolite plays a physiological role in the brain as | preclinical |

| | | |
|---|---|---|
| | an inhibitory regulator of catecholaminergic activity | |
| Balijepalli, S.-//-Boyd, M. R.-//-Ravindranath, V. | Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation | preclinical |
| Balijepalli, S.-//-Kenchappa, R. S.-//-Boyd, M. R.-//-Ravindranath, V. | Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics | preclinical |
| Barrientos, A.-//-Marín, C.-//-Miró, O.-//-Casademont, J.-//-Gómez, M.-//-Nunes, V.-//-Tolosa, E.-//-Urbano-Márquez, A.-//-Cardellach, F. | Biochemical and molecular effects of chronic haloperidol administration on brain and muscle mitochondria of rats | preclinical |
| Bar-Yosef, T.-//-Hussein, W.-//-Yitzhaki, O.-//-Damri, O.-//-Givon, L.-//-Marom, C.-//-Gurman, V.-//-Levine, J.-//-Bersudsky, Y.-//-Agam, G.-//-Ben-Shachar, D. | Mitochondrial function parameters as a tool for tailored drug treatment of an individual with psychosis: a proof of concept study | preclinical |
| Ben-Shachar, D. | Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine | review |
| Ben-Shachar, D. | Mitochondrial multifaceted dysfunction in schizophrenia; complex I as a possible pathological target | review |
| Ben-Shachar, D.-//-Karry, R. | Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression | preclinical |
| Bentsen, H.-//-Osnes, K.-//-Refsum, H.-//-Solberg, D. K.-//-Bøhmer, T. | A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia | clinical |
| Bergman, O.-//-Ben-Shachar, D. | Mitochondrial Oxidative Phosphorylation System (OXPHOS) Deficits in Schizophrenia: Possible Interactions with Cellular Processes | review |
| Berk, M.-//-Copolov, D.-//-Dean, O.-//-Lu, K.-//-Jeavons, S.-//-Schapkaitz, I.-//-Anderson-Hunt, M.-//-Judd, F.-//-Katz, F.-//-Katz, P.-//-Ording-Jespersen, S.-//-Little, J.-//-Conus, P.-//-Cuenod, M.-//-Do, K. Q.-//-Bush, A. I. | N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial | clinical |
| Bertholet, A. M.-//-Millet, A. M.-//-Guillermin, O.-//-Daloyau, M.-//-Davezac, N.-//-Miquel, M. C.-//-Belenguer, P. | OPA1 loss of function affects in vitro neuronal maturation | preclinical |
| Bodhinathan, K.-//-Kumar, A.-//-Foster, T. C. | Intracellular redox state alters NMDA receptor response during aging through Ca2+/calmodulin-dependent protein kinase II | preclinical |
| Bošković, M.-//-Vovk, T.-//-Koprivšek, J.-//-Plesničar, B. K.-//-Grabnar, I. | Vitamin E and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol | clinical |
| Boz, Z.-//-Hu, M.-//-Yu, Y.-//-Huang, X. F. | N-acetylcysteine prevents olanzapine-induced oxidative stress in mHypoA-59 hypothalamic neurons | preclinical |

| | | |
|---|---|---|
| Breier, A.-//-Liffick, E.-//-Hummer, T. A.-//-Vohs, J. L.-//-Yang, Z.-//-Mehdiyoun, N. F.-//-Visco, A. C.-//-Metzler, E.-//-Zhang, Y.-//-Francis, M. M. | Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders | clinical |
| Brenman, Jay E.-//-Chao, Daniel S.-//-Gee, Stephen H.-//-McGee, Aaron W.-//-Craven, Sarah E.-//-Santillano, Daniel R.-//-Wu, Ziqiang-//-Huang, Fred-//-Xia, Houhui-//-Peters, Matthew F.-//-Froehner, Stanley C.-//-Bredt, David S. | Interaction of Nitric Oxide Synthase with the Postsynaptic Density Protein PSD-95 and α1-Syntrophin Mediated by PDZ Domains | preclinical |
| Brinholi, F. F.-//-Farias, C. C.-//-Bonifácio, K. L.-//-Higachi, L.-//-Casagrande, R.-//-Moreira, E. G.-//-Barbosa, D. S. | Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models | preclinical |
| Brunstein, M. G.-//-Ghisolfi, E. S.-//-Ramos, F. L.-//-Lara, D. R. | A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia | clinical |
| Buonaguro, E. F.-//-Tomasetti, C.-//-Chiodini, P.-//-Marmo, F.-//-Latte, G.-//-Rossi, R.-//-Avvisati, L.-//-Iasevoli, F.-//-de Bartolomeis, A. | Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia | preclinical |
| Buosi, P.-//-Borghi, F. A.-//-Lopes, A. M.-//-Facincani, I. D. S.-//-Fernandes-Ferreira, R.-//-Oliveira-Brancati, C. I. F.-//-do Carmo, T. S.-//-Souza, D. R. S.-//-da Silva, D. G. H.-//-de Almeida, E. A.-//-de Araújo Filho, G. M. | Oxidative stress biomarkers in treatment-responsive and treatment-resistant schizophrenia patients | clinical |
| Burkhardt, C.-//-Kelly, J. P.-//-Lim, Y. H.-//-Filley, C. M.-//-Parker, W. D., Jr. | Neuroleptic medications inhibit complex I of the electron transport chain | preclinical |
| Cabungcal, J. H.-//-Steullet, P.-//-Morishita, H.-//-Kraftsik, R.-//-Cuenod, M.-//-Hensch, T. K.-//-Do, K. Q. | Perineuronal nets protect fast-spiking interneurons against oxidative stress | preclinical |
| Cabungcal, J. H.-//-Counotte, D. S.-//-Lewis, E.-//-Tejeda, H. A.-//-Piantadosi, P.-//-Pollock, C.-//-Calhoon, G. G.-//-Sullivan, E.-//-Presgraves, E.-//-Kil, J.-//-Hong, L. E.-//-Cuenod, M.-//-Do, K. Q.-//-O'Donnell, P. | Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia | preclinical |
| Cabungcal, J. H.-//-Steullet, P.-//-Kraftsik, R.-//-Cuenod, M.-//-Do, K. Q. | A developmental redox dysregulation leads to spatio-temporal deficit of parvalbumin neuron circuitry in a schizophrenia mouse model | preclinical |
| Cardis, R.-//-Cabungcal, J. H.-//-Dwir, D.-//-Do, K. Q.-//-Steullet, P. | A lack of GluN2A-containing NMDA receptors confers a vulnerability to redox dysregulation: Consequences on parvalbumin interneurons, and their perineuronal nets | preclinical |

| | | |
|---|---|---|
| Carmeli, C.-//-Knyazeva, M. G.-//-Cuénod, M.-//-Do, K. Q. | Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial | clinical |
| Caruso, G.-//-Grasso, M.-//-Fidilio, A.-//-Tascedda, F.-//-Drago, F.-//-Caraci, F. | Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia | review |
| Casademont, J.-//-Garrabou, G.-//-Miró, O.-//-López, S.-//-Pons, A.-//-Bernardo, M.-//-Cardellach, F. | Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients | clinical |
| Celano, E.-//-Tiraboschi, E.-//-Consogno, E.-//-D'Urso, G.-//-Mbakop, M. P.-//-Gennarelli, M.-//-de Bartolomeis, A.-//-Racagni, G.-//-Popoli, M. | Selective regulation of presynaptic calcium/calmodulin-dependent protein kinase II by psychotropic drugs | preclinical |
| Chan, S. T.-//-McCarthy, M. J.-//-Vawter, M. P. | Psychiatric drugs impact mitochondrial function in brain and other tissues | review |
| Chen, B. H.-//-Yan, B. C.-//-Park, J. H.-//-Ahn, J. H.-//-Lee, D. H.-//-Kim, I. H.-//-Cho, J. H.-//-Lee, J. C.-//-Kim, S. K.-//-Lee, B.-//-Cho, J. H.-//-Won, M. H.-//-Lee, Y. L. | Aripiprazole, an atypical antipsychotic drug, improves maturation and complexity of neuroblast dendrites in the mouse dentate gyrus via increasing superoxide dismutases | preclinical |
| Chen, H.-//-Detmer, S. A.-//-Ewald, A. J.-//-Griffin, E. E.-//-Fraser, S. E.-//-Chan, D. C. | Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development | preclinical |
| Chen, H.-//-McCaffery, J. M.-//-Chan, D. C. | Mitochondrial fusion protects against neurodegeneration in the cerebellum | preclinical |
| Choi, Y.-//-Chen, H. V.-//-Lipton, S. A. | Three pairs of cysteine residues mediate both redox and zn2+ modulation of the nmda receptor | preclinical |
| Chua, J. S.-//-Cowley, C. J.-//-Manavis, J.-//-Rofe, A. M.-//-Coyle, P. | Prenatal exposure to lipopolysaccharide results in neurodevelopmental damage that is ameliorated by zinc in mice | preclinical |
| Corcoba, A.-//-Steullet, P.-//-Duarte, J. M.-//-Van de Looij, Y.-//-Monin, A.-//-Cuenod, M.-//-Gruetter, R.-//-Do, K. Q. | Glutathione Deficit Affects the Integrity and Function of the Fimbria/Fornix and Anterior Commissure in Mice: Relevance for Schizophrenia | preclinical |
| Corti, C.-//-Xuereb, J. H.-//-Crepaldi, L.-//-Corsi, M.-//-Michielin, F.-//-Ferraguti, F. | Altered levels of glutamatergic receptors and Na+/K+ ATPase-α1 in the prefrontal cortex of subjects with schizophrenia | preclinical |
| Dakhale, G. N.-//-Khanzode, S. D.-//-Khanzode, S. S.-//-Saoji, A. | Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia | clinical |
| Das, T. K.-//-Javadzadeh, A.-//-Dey, A.-//-Sabesan, P.-//-Théberge, J.-//-Radua, J.-//-Palaniyappan, L. | Antioxidant defense in schizophrenia and bipolar disorder: A meta-analysis of MRS studies of anterior cingulate glutathione | review |
| Davies, V. J.-//-Hollins, A. J.-//-Piechota, M. J.-//-Yip, W.-//-Davies, J. R.-//-White, K. E.-//- | Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function | preclinical |

| | | |
|---|---|---|
| Nicols, P. P.-//-Boulton, M. E.-//-Votruba, M. | | |
| de Bartolomeis, A.-//-Barone, A.-//-Vellucci, L.-//-Mazza, B.-//-Austin, M. C.-//-Iasevoli, F.-//-Ciccarelli, M. | Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review | review |
| De Lima, D. N., Jr.-//-Costa Filho, C. W. L.-//-Frota, I. J.-//-de Oliveira, A. L. B.-//-Menezes, C. E. S.-//-Chaves Filho, A. J. M.-//-Viana, G. A.-//-Campos, E. M.-//-Collares, M.-//-de Queiroz, M. G. R.-//-da Cruz Fonseca, S. G.-//-Vasconcelos, S. M. M.-//-Macêdo, D. S.-//-Sanders, L. L. O. | α-Lipoic Acid as Adjunctive Treatment for Schizophrenia: A Randomized Double-Blind Study | clinical |
| Devine, M. J.-//-Kittler, J. T. | Mitochondria at the neuronal presynapse in health and disease | review |
| Dickerson, F. B.-//-Stallings, C. R.-//-Origoni, A. E.-//-Sullens, A.-//-Khushalani, S.-//-Sandson, N.-//-Yolken, R. H. | A double-blind trial of adjunctive allopurinol for schizophrenia | clinical |
| Dietrich-Muszalska, A.-//-Kopka, J.-//-Kwiatkowska, A. | The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison | clinical |
| Dietrich-Muszalska, A.-//-Kolińska-Łukaszuk, J. | Comparative effects of aripiprazole and selected antipsychotic drugs on lipid peroxidation in plasma | clinical |
| Do, K. Q.-//-Trabesinger, A. H.-//-Kirsten-Krüger, M.-//-Lauer, C. J.-//-Dydak, U.-//-Hell, D.-//-Holsboer, F.-//-Boesiger, P.-//-Cuénod, M. | Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo | clinical |
| Do, K. Q.-//-Cabungcal, J. H.-//-Frank, A.-//-Steullet, P.-//-Cuenod, M. | Redox dysregulation, neurodevelopment, and schizophrenia | review |
| Do, K. Q.-//-Cuenod, M.-//-Hensch, T. K. | Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia | review |
| Dorevitch, A.-//-Kalian, M.-//-Shlafman, M.-//-Lerner, V. | Treatment of long-term tardive dyskinesia with vitamin E | clinical |
| Doruk, A.-//-Uzun, O.-//-Ozşahin, A. | A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia | clinical |
| Elimadi, A.-//-Bouillot, L.-//-Sapena, R.-//-Tillement, J. P.-//-Morin, D. | Dose-related inversion of cinnarizine and flunarizine effects on mitochondrial permeability transition | preclinical |
| Elkashef, A. M.-//-Al-Barazi, H.-//-Venable, D.-//-Baker, I.-//-Hill, J.-//-Apud, J.-//-Wyatt, R. J. | Dopamine effect on the mitochondria potential in B lymphocytes of schizophrenic patients and normal controls | preclinical |
| Elmorsy, E.-//-Alelwani, W.-//-Kattan, S.-//-Babteen, N.-//-Alnajeebi, A.-//-Ghulam, J.-//-Mosad, S. | Antipsychotics inhibit the mitochondrial bioenergetics of pancreatic beta cells isolated from CD1 mice | preclinical |

| | | |
|---|---|---|
| Ertürk, A.-//-Wang, Y.-//-Sheng, M. | Local pruning of dendrites and spines by caspase-3-dependent and proteasome-limited mechanisms | preclinical |
| Farokhnia, M.-//-Azarkolah, A.-//-Adinehfar, F.-//-Khodaie-Ardakani, M. R.-//-Hosseini, S. M.-//-Yekehtaz, H.-//-Tabrizi, M.-//-Rezaei, F.-//-Salehi, B.-//-Sadeghi, S. M.-//-Moghadam, M.-//-Gharibi, F.-//-Mirshafiee, O.-//-Akhondzadeh, S. | N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study | clinical |
| Fernandez-Fernandez, S.-//-Bobo-Jimenez, V.-//-Requejo-Aguilar, R.-//-Gonzalez-Fernandez, S.-//-Resch, M.-//-Carabias-Carrasco, M.-//-Ros, J.-//-Almeida, A.-//-Bolaños, J. P. | Hippocampal neurons require a large pool of glutathione to sustain dendrite integrity and cognitive function | preclinical |
| Ferraris, D.-//-Duvall, B.-//-Ko, Y. S.-//-Thomas, A. G.-//-Rojas, C.-//-Majer, P.-//-Hashimoto, K.-//-Tsukamoto, T. | Synthesis and biological evaluation of D-amino acid oxidase inhibitors | preclinical |
| Flippo, K. H.-//-Strack, S. | An emerging role for mitochondrial dynamics in schizophrenia | review |
| Forder, J. P.-//-Tymianski, M. | Postsynaptic mechanisms of excitotoxicity: Involvement of postsynaptic density proteins, radicals, and oxidant molecules | review |
| Freudenberg, F.-//-Alttoa, A.-//-Reif, A. | Neuronal nitric oxide synthase (NOS1) and its adaptor, NOS1AP, as a genetic risk factors for psychiatric disorders | review |
| Frey, B. N.-//-Valvassori, S. S.-//-Gomes, K. M.-//-Martins, M. R.-//-Dal-Pizzol, F.-//-Kapczinski, F.-//-Quevedo, J. | Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure | preclinical |
| Freyberg, Z.-//-Ferrando, S. J.-//-Javitch, J. A. | Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action | review |
| Gassó, P.-//-Mas, S.-//-Molina, O.-//-Bernardo, M.-//-Lafuente, A.-//-Parellada, E. | Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells | preclinical |
| Goh, X. X.-//-Tang, P. Y.-//-Tee, S. F. | Effects of antipsychotics on antioxidant defence system in patients with schizophrenia: A meta-analysis | review |
| Górny, M.-//-Bilska-Wilkosz, A.-//-Iciek, M.-//-Hereta, M.-//-Kamińska, K.-//-Kamińska, A.-//-Chwatko, G.-//-Rogóż, Z.-//-Lorenc-Koci, E. | Alterations in the Antioxidant Enzyme Activities in the Neurodevelopmental Rat Model of Schizophrenia Induced by Glutathione Deficiency during Early Postnatal Life | preclinical |
| Grima, G.-//-Benz, B.-//-Parpura, V.-//-Cuénod, M.-//-Do, K. Q. | Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia | preclinical |
| Hashimoto, K.-//-Fujita, Y.-//-Horio, M.-//-Kunitachi, S.-//-Iyo, | Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in | preclinical |

| | | |
|---|---|---|
| M.-//-Ferraris, D.-//-Tsukamoto, T. | attenuating prepulse inhibition deficits after administration of dizocilpine | |
| Hendouei, N.-//-Farnia, S.-//-Mohseni, F.-//-Salehi, A.-//-Bagheri, M.-//-Shadfar, F.-//-Barzegar, F.-//-Hoseini, S. D.-//-Charati, J. Y.-//-Shaki, F. | Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone | clinical |
| Hirata, Y.-//-Oka, K.-//-Yamamoto, S.-//-Watanabe, H.-//-Oh-Hashi, K.-//-Hirayama, T.-//-Nagasawa, H.-//-Takemori, H.-//-Furuta, K. | Haloperidol Prevents Oxytosis/Ferroptosis by Targeting Lysosomal Ferrous Ions in a Manner Independent of Dopamine D2 and Sigma-1 Receptors | preclinical |
| Huang, C. H.-//-Fu, S. H.-//-Hsu, S.-//-Huang, Y. Y.-//-Chen, S. T.-//-Hsu, B. R. | High-fat diet aggravates islet beta-cell toxicity in mice treated with clozapine | preclinical |
| Iasevoli, F.-//-Buonaguro, E. F.-//-Avagliano, C.-//-Barone, A.-//-Eramo, A.-//-Vellucci, L.-//-de Bartolomeis, A. | The Effects of Antipsychotics on the Synaptic Plasticity Gene Homer1a Depend on a Combination of Their Receptor Profile, Dose, Duration of Treatment, and Brain Regions Targeted | preclinical |
| Iwata, Y.-//-Nakajima, S.-//-Plitman, E.-//-Truong, P.-//-Bani-Fatemi, A.-//-Caravaggio, F.-//-Kim, J.-//-Shah, P.-//-Mar, W.-//-Chavez, S.-//-Remington, G.-//-Gerretsen, P.-//-De Luca, V.-//-Sailasuta, N.-//-Graff-Guerrero, A. | Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia | clinical |
| Jahan, M. S.-//-Tsuzuki, T.-//-Ito, T.-//-Bhuiyan, M. E. R.-//-Takahashi, I.-//-Takamatsu, H.-//-Kumanogoh, A.-//-Negishi, T.-//-Yukawa, K. | PlexinA1-deficient mice exhibit decreased cell density and augmented oxidative stress in parvalbumin-expressing interneurons in the medial prefrontal cortex | preclinical |
| Ji, B.-//-La, Y.-//-Gao, L.-//-Zhu, H.-//-Tian, N.-//-Zhang, M.-//-Yang, Y.-//-Zhao, X.-//-Tang, R.-//-Ma, G.-//-Zhou, J.-//-Meng, J.-//-Ma, J.-//-Zhang, Z.-//-Li, H.-//-Feng, G.-//-Wang, Y.-//-He, L.-//-Wan, C. | A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications | preclinical |
| Jiao, S.-//-Cao, T.-//-Cai, H. | Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives | review |
| Kilanczyk, E.-//-Saraswat Ohri, S.-//-Whittemore, S. R.-//-Hetman, M. | Antioxidant Protection of NADPH-Depleted Oligodendrocyte Precursor Cells Is Dependent on Supply of Reduced Glutathione | preclinical |
| Kim, H. K.-//-Andreazza, A. C. | The relationship between oxidative stress and post-translational modification of the dopamine transporter in bipolar disorder | review |
| Kim, Y.-//-Vadodaria, K. C.-//-Lenkei, Z.-//-Kato, T.-//-Gage, F. | Mitochondria, Metabolism, and Redox Mechanisms in Psychiatric Disorders | review |

| | | |
|---|---|---|
| H.-//-Marchetto, M. C.-//-Santos, R. | | |
| Klauser, P.-//-Xin, L.-//-Fournier, M.-//-Griffa, A.-//-Cleusix, M.-//-Jenni, R.-//-Cuenod, M.-//-Gruetter, R.-//-Hagmann, P.-//-Conus, P.-//-Baumann, P. S.-//-Do, K. Q. | N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial | clinical |
| Kung, L.-//-Roberts, R. C. | Mitochondrial pathology in human schizophrenic striatum: a postmortem ultrastructural study | preclinical |
| Kvajo, M.-//-Dhilla, A.-//-Swor, D. E.-//-Karayiorgou, M.-//-Gogos, J. A. | Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function | preclinical |
| Kwon, D. J.-//-Ju, S. M.-//-Youn, G. S.-//-Choi, S. Y.-//-Park, J. | Suppression of iNOS and COX-2 expression by flavokawain A via blockade of NF-κB and AP-1 activation in RAW 264.7 macrophages | preclinical |
| Lavoie, S.-//-Murray, M. M.-//-Deppen, P.-//-Knyazeva, M. G.-//-Berk, M.-//-Boulat, O.-//-Bovet, P.-//-Bush, A. I.-//-Conus, P.-//-Copolov, D.-//-Fornari, E.-//-Meuli, R.-//-Solida, A.-//-Vianin, P.-//-Cuénod, M.-//-Buclin, T.-//-Do, K. Q. | Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients | clinical |
| Lech, M. A.-//-Leśkiewicz, M.-//-Kamińska, K.-//-Rogóż, Z.-//-Lorenc-Koci, E. | Glutathione Deficiency during Early Postnatal Development Causes Schizophrenia-Like Symptoms and a Reduction in BDNF Levels in the Cortex and Hippocampus of Adult Sprague-Dawley Rats | preclinical |
| Limongi, R.-//-Jeon, P.-//-Théberge, J.-//-Palaniyappan, L. | Counteracting Effects of Glutathione on the Glutamate-Driven Excitation/Inhibition Imbalance in First-Episode Schizophrenia: A 7T MRS and Dynamic Causal Modeling Study | clinical |
| Liu, H.-//-Liu, H.-//-Jiang, S.-//-Su, L.-//-Lu, Y.-//-Chen, Z.-//-Li, X.-//-Li, X.-//-Wang, X.-//-Xiu, M.-//-Zhang, X. | Sex-Specific Association between Antioxidant Defense System and Therapeutic Response to Risperidone in Schizophrenia: A Prospective Longitudinal Study | clinical |
| Liu, H.-//-Yu, R.-//-Gao, Y.-//-Li, X.-//-Guan, X.-//-Thomas, K.-//-Xiu, M.-//-Zhang, X. | Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study | clinical |
| Lopes-Rocha, A.-//-Bezerra, T. O.-//-Zanotto, R.-//-Lages Nascimento, I.-//-Rodrigues, A.-//-Salum, C. | The Antioxidant N-Acetyl-L-Cysteine Restores the Behavioral Deficits in a Neurodevelopmental Model of Schizophrenia Through a Mechanism That Involves Nitric Oxide | preclinical |
| Maas, D. A.-//-Eijsink, V. D.-//-van Hulten, J. A.-//-Panic, R.-//-De Weerd, P.-//-Homberg, J. R.-//-Vallès, A.-//-Nait-Oumesmar, B.-//-Martens, G. J. M. | Antioxidant treatment ameliorates prefrontal hypomyelination and cognitive deficits in a rat model of schizophrenia | preclinical |

| | | |
|---|---|---|
| MacDowell, K. S.-//-Martín-Hernández, D.-//-Ulecia-Morón, C.-//-Bris Á, G.-//-Madrigal, J. L. M.-//-García-Bueno, B.-//-Caso, J. R. | Paliperidone attenuates chronic stress-induced changes in the expression of inflammasomes-related protein in the frontal cortex of male rats | preclinical |
| Magalhães, P. V.-//-Dean, O.-//-Andreazza, A. C.-//-Berk, M.-//-Kapczinski, F. | Antioxidant treatments for schizophrenia | review |
| Marchbanks, R. M.-//-Ryan, M.-//-Day, I. N.-//-Owen, M.-//-McGuffin, P.-//-Whatley, S. A. | A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress | preclinical |
| Marí, M.-//-Morales, A.-//-Colell, A.-//-García-Ruiz, C.-//-Fernández-Checa, J. C. | Mitochondrial glutathione, a key survival antioxidant | review |
| Masoud, S. T.-//-Vecchio, L. M.-//-Bergeron, Y.-//-Hossain, M. M.-//-Nguyen, L. T.-//-Bermejo, M. K.-//-Kile, B.-//-Sotnikova, T. D.-//-Siesser, W. B.-//-Gainetdinov, R. R.-//-Wightman, R. M.-//-Caron, M. G.-//-Richardson, J. R.-//-Miller, G. W.-//-Ramsey, A. J.-//-Cyr, M.-//-Salahpour, A. | Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits | preclinical |
| Maurer, I.-//-Möller, H. J. | Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics | preclinical |
| Maurer, I.-//-Zierz, S.-//-Möller, H. | Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia | preclinical |
| Meade, A. J.-//-Meloni, B. P.-//-Cross, J.-//-Bakker, A. J.-//-Fear, M. W.-//-Mastaglia, F. L.-//-Watt, P. M.-//-Knuckey, N. W. | AP-1 inhibitory peptides are neuroprotective following acute glutamate excitotoxicity in primary cortical neuronal cultures | preclinical |
| Millar, J. K.-//-James, R.-//-Christie, S.-//-Porteous, D. J. | Disrupted in schizophrenia 1 (DISC1): subcellular targeting and induction of ring mitochondria | preclinical |
| Mishra, A.-//-Reeta, K. H.-//-Sarangi, S. C.-//-Maiti, R.-//-Sood, M. | Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial | clinical |
| Monin, A.-//-Baumann, P. S.-//-Griffa, A.-//-Xin, L.-//-Mekle, R.-//-Fournier, M.-//-Butticaz, C.-//-Klaey, M.-//-Cabungcal, J. H.-//-Steullet, P.-//-Ferrari, C.-//-Cuenod, M.-//-Gruetter, R.-//-Thiran, J. P.-//-Hagmann, P.-//-Conus, P.-//-Do, K. Q. | Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients | clinical |
| Mullier, E.-//-Roine, T.-//-Griffa, A.-//-Xin, L.-//-Baumann, P. S.-//-Klauser, P.-//-Cleusix, M.-//-Jenni, R.-//-Alemàn-Gómez, Y.- | N-Acetyl-Cysteine Supplementation Improves Functional Connectivity Within the Cingulate Cortex in Early Psychosis: A Pilot Study | clinical |

| | | |
|---|---|---|
| //-Gruetter, R.-//-Conus, P.-//-Do, K. Q.-//-Hagmann, P. | | |
| Munakata, K.-//-Iwamoto, K.-//-Bundo, M.-//-Kato, T. | Mitochondrial DNA 3243A>G mutation and increased expression of LARS2 gene in the brains of patients with bipolar disorder and schizophrenia | preclinical |
| Musazzi, L.-//-Treccani, G.-//-Popoli, M. | Functional and structural remodeling of glutamate synapses in prefrontal and frontal cortex induced by behavioral stress | review |
| Myken, A. N.-//-Ebdrup, B. H.-//-Sørensen, M. E.-//-Broberg, B. V.-//-Skjerbæk, M. W.-//-Glenthøj, B. Y.-//-Lykkesfeldt, J.-//-Nielsen, MØ | Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis | clinical |
| Naoi, Makoto-//-Maruyama, Wakako-//-Shamoto-Nagai, Masayo | Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies | review |
| Neill, E.-//-Rossell, S. L.-//-Yolland, C.-//-Meyer, D.-//-Galletly, C.-//-Harris, A.-//-Siskind, D.-//-Berk, M.-//-Bozaoglu, K.-//-Dark, F.-//-Dean, O. M.-//-Francis, P. S.-//-Liu, D.-//-Phillipou, A.-//-Sarris, J.-//-Castle, D. J. | N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms | clinical |
| Nepliouev, I.-//-Zhang, Z. S.-//-Stiber, J. A. | Effect of oxidative stress on homer scaffolding proteins | preclinical |
| Ninan, I.-//-Jardemark, K. E.-//-Liang, X.-//-Wang, R. Y. | Calcium/calmodulin-dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically evoked responses in the medial prefrontal cortical pyramidal cells | preclinical |
| Norkett, R.-//-Modi, S.-//-Birsa, N.-//-Atkin, T. A.-//-Ivankovic, D.-//-Pathania, M.-//-Trossbach, S. V.-//-Korth, C.-//-Hirst, W. D.-//-Kittler, J. T. | DISC1-dependent Regulation of Mitochondrial Dynamics Controls the Morphogenesis of Complex Neuronal Dendrites | preclinical |
| Page, M. J.-//-McKenzie, J. E.-//-Bossuyt, P. M.-//-Boutron, I.-//-Hoffmann, T. C.-//-Mulrow, C. D.-//-Shamseer, L.-//-Tetzlaff, J. M.-//-Akl, E. A.-//-Brennan, S. E.-//-Chou, R.-//-Glanville, J.-//-Grimshaw, J. M.-//-Hróbjartsson, A.-//-Lalu, M. M.-//-Li, T.-//-Loder, E. W.-//-Mayo-Wilson, E.-//-McDonald, S.-//-McGuinness, L. A.-//-Stewart, L. A.-//-Thomas, J.-//-Tricco, A. C.-//-Welch, V. A.-//-Whiting, P.-//-Moher, D. | The PRISMA 2020 statement: an updated guideline for reporting systematic reviews | review |
| Palaniyappan, L.-//-Park, M. T. M.-//-Jeon, P.-//-Limongi, R.-//- | Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia? | review |

| | | |
|---|---|---|
| Yang, K.-//-Sawa, A.-//-Théberge, J. | | |
| Pandurangi, A. K.-//-Buckley, P. F. | Inflammation, Antipsychotic Drugs, and Evidence for Effectiveness of Anti-inflammatory Agents in Schizophrenia | review |
| Park, S. U.-//-Ferrer, J. V.-//-Javitch, J. A.-//-Kuhn, D. M. | Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons | preclinical |
| Pedrini, M.-//-Massuda, R.-//-Fries, G. R.-//-de Bittencourt Pasquali, M. A.-//-Schnorr, C. E.-//-Moreira, J. C.-//-Teixeira, A. L.-//-Lobato, M. I.-//-Walz, J. C.-//-Belmonte-de-Abreu, P. S.-//-Kauer-Sant'Anna, M.-//-Kapczinski, F.-//-Gama, C. S. | Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity | clinical |
| Perez-Cruz, C.-//-Müller-Keuker, J. I.-//-Heilbronner, U.-//-Fuchs, E.-//-Flügge, G. | Morphology of pyramidal neurons in the rat prefrontal cortex: lateralized dendritic remodeling by chronic stress | preclinical |
| Phensy, A.-//-Duzdabanian, H. E.-//-Brewer, S.-//-Panjabi, A.-//-Driskill, C.-//-Berz, A.-//-Peng, G.-//-Kroener, S. | Antioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine Treatment | preclinical |
| Pillai, A.-//-Veeranan-Karmegam, R.-//-Dhandapani, K. M.-//-Mahadik, S. P. | Cystamine prevents haloperidol-induced decrease of BDNF/TrkB signaling in mouse frontal cortex | preclinical |
| Pillinger, T.-//-D'Ambrosio, E.-//-McCutcheon, R.-//-Howes, O. D. | Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models | review |
| Prince, J. A.-//-Yassin, M. S.-//-Oreland, L. | Neuroleptic-induced mitochondrial enzyme alterations in the rat brain | preclinical |
| Rambaud, V.-//-Marzo, A.-//-Chaumette, B. | Oxidative Stress and Emergence of Psychosis | review |
| Rapado-Castro, M.-//-Berk, M.-//-Venugopal, K.-//-Bush, A. I.-//-Dodd, S.-//-Dean, O. M. | Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia | clinical |
| Rapado-Castro, M.-//-Dodd, S.-//-Bush, A. I.-//-Malhi, G. S.-//-Skvarc, D. R.-//-On, Z. X.-//-Berk, M.-//-Dean, O. M. | Cognitive effects of adjunctive N-acetyl cysteine in psychosis | clinical |
| Raudenska, M.-//-Gumulec, J.-//-Babula, P.-//-Stracina, T.-//-Sztalmachova, M.-//-Polanska, H.-//-Adam, V.-//-Kizek, R.-//-Novakova, M.-//-Masarik, M. | Haloperidol cytotoxicity and its relation to oxidative stress | review |
| Rice, M. W.-//-Smith, K. L.-//-Roberts, R. C.-//-Perez-Costas, E.-//-Melendez-Ferro, M. | Assessment of cytochrome C oxidase dysfunction in the substantia nigra/ventral tegmental area in schizophrenia | preclinical |

| | | |
|---|---|---|
| Rollins, B. L.-//-Morgan, L.-//-Hjelm, B. E.-//-Sequeira, A.-//-Schatzberg, A. F.-//-Barchas, J. D.-//-Lee, F. S.-//-Myers, R. M.-//-Watson, S. J.-//-Akil, H.-//-Potkin, S. G.-//-Bunney, W. E.-//-Vawter, M. P. | Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence | preclinical |
| Rosenfeld, M.-//-Brenner-Lavie, H.-//-Ari, S. G.-//-Kavushansky, A.-//-Ben-Shachar, D. | Perturbation in mitochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia | preclinical |
| Rushlow, W. J.-//-Seah, C.-//-Sutton, L. P.-//-Bjelica, A.-//-Rajakumar, N. | Antipsychotics affect multiple calcium calmodulin dependent proteins | preclinical |
| Sacchi, S.-//-Novellis, V.-//-Paolone, G.-//-Nuzzo, T.-//-Iannotta, M.-//-Belardo, C.-//-Squillace, M.-//-Bolognesi, P.-//-Rosini, E.-//-Motta, Z.-//-Frassineti, M.-//-Bertolino, A.-//-Pollegioni, L.-//-Morari, M.-//-Maione, S.-//-Errico, F.-//-Usiello, A. | Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity | preclinical |
| Sagara, Y. | Induction of reactive oxygen species in neurons by haloperidol | preclinical |
| Scaini, G.-//-Quevedo, J.-//-Velligan, D.-//-Roberts, D. L.-//-Raventos, H.-//-Walss-Bass, C. | Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia | preclinical |
| Schumacher, J.-//-Jamra, R. A.-//-Freudenberg, J.-//-Becker, T.-//-Ohlraun, S.-//-Otte, A. C.-//-Tullius, M.-//-Kovalenko, S.-//-Bogaert, A. V.-//-Maier, W.-//-Rietschel, M.-//-Propping, P.-//-Nöthen, M. M.-//-Cichon, S. | Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder | preclinical |
| Semenovich, D. S.-//-Plotnikov, E. Y.-//-Titko, O. V.-//-Lukiyenko, E. P.-//-Kanunnikova, N. P. | Effects of Panthenol and N-Acetylcysteine on Changes in the Redox State of Brain Mitochondria under Oxidative Stress In Vitro | preclinical |
| Sepehrmanesh, Z.-//-Heidary, M.-//-Akasheh, N.-//-Akbari, H.-//-Heidary, M. | Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial | clinical |
| Seybolt, S. E. | Is it time to reassess alpha lipoic acid and niacinamide therapy in schizophrenia? | review |
| Singh, O. P.-//-Chakraborty, I.-//-Dasgupta, A.-//-Datta, S. | A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia | clinical |
| Smith, G. A.-//-Lin, T. H.-//-Sheehan, A. E.-//-Van der Goes van Naters, W.-//-Neukomm, L. J.-//-Graves, H. K.-//-Bis-Brewer, | Glutathione S-Transferase Regulates Mitochondrial Populations in Axons through Increased Glutathione Oxidation | preclinical |

| | | |
|---|---|---|
| D. M.-//-Züchner, S.-//-Freeman, M. R. | | |
| Somerville, S. M.-//-Lahti, A. C.-//-Conley, R. R.-//-Roberts, R. C. | Mitochondria in the striatum of subjects with schizophrenia: relationship to treatment response | preclinical |
| Subramanyam, B.-//-Rollema, H.-//-Woolf, T.-//-Castagnoli, N., Jr. | Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats | preclinical |
| Sun, J.-//-Zhang, X.-//-Cong, Q.-//-Chen, D.-//-Yi, Z.-//-Huang, H.-//-Wang, C.-//-Li, M.-//-Zeng, R.-//-Liu, Y.-//-Huai, C.-//-Chen, L.-//-Liu, C.-//-Zhang, Y.-//-Xu, Y.-//-Fan, L.-//-Wang, G.-//-Song, C.-//-Wei, M.-//-Du, H.-//-Zhu, J.-//-He, L.-//-Qin, S. | miR143-3p-Mediated NRG-1-Dependent Mitochondrial Dysfunction Contributes to Olanzapine Resistance in Refractory Schizophrenia | preclinical |
| Svane, K. C.-//-Asis, E. K.-//-Omelchenko, A.-//-Kunnath, A. J.-//-Brzustowicz, L. M.-//-Silverstein, S. M.-//-Firestein, B. L. | d-Serine administration affects nitric oxide synthase 1 adaptor protein and DISC1 expression in sex-specific manner | preclinical |
| Swanepoel, T.-//-Möller, M.-//-Harvey, B. H. | N-acetyl cysteine reverses bio-behavioural changes induced by prenatal inflammation, adolescent methamphetamine exposure and combined challenges | preclinical |
| Tsugawa, S.-//-Noda, Y.-//-Tarumi, R.-//-Mimura, Y.-//-Yoshida, K.-//-Iwata, Y.-//-Elsalhy, M.-//-Kuromiya, M.-//-Kurose, S.-//-Masuda, F.-//-Morita, S.-//-Ogyu, K.-//-Plitman, E.-//-Wada, M.-//-Miyazaki, T.-//-Graff-Guerrero, A.-//-Mimura, M.-//-Nakajima, S. | Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis | review |
| Ueno, H.-//-Nishigaki, Y.-//-Kong, Q. P.-//-Fuku, N.-//-Kojima, S.-//-Iwata, N.-//-Ozaki, N.-//-Tanaka, M. | Analysis of mitochondrial DNA variants in Japanese patients with schizophrenia | preclinical |
| Uludag, K.-//-Wang, D. M.-//-Zhang, X. Y. | Tardive Dyskinesia Development, Superoxide Dismutase Levels, and Relevant Genetic Polymorphisms | review |
| Unsal, C.-//-Albayrak, Y.-//-Albayrak, N.-//-Kuloglu, M.-//-Hashimoto, K. | Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine | clinical |
| Wąsik, A.-//-Białoń, M.-//-Żarnowska, M.-//-Antkiewicz-Michaluk, L. | Comparison of the effects of 1MeTIQ and olanzapine on performance in the elevated plus maze test and monoamine metabolism in the brain after ketamine treatment | preclinical |
| Wei, Z.-//-Bai, O.-//-Richardson, J. S.-//-Mousseau, D. D.-//-Li, X. M. | Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide | preclinical |

| | | |
|---|---|---|
| Weiden, P. J.-//-Breier, A.-//-Kavanagh, S.-//-Miller, A. C.-//-Brannan, S. K.-//-Paul, S. M. | Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study | clinical |
| Weiser, M.-//-Gershon, A. A.-//-Rubinstein, K.-//-Petcu, C.-//-Ladea, M.-//-Sima, D.-//-Podea, D.-//-Keefe, R. S.-//-Davis, J. M. | A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder | clinical |
| Weng, Yu-Ting-//-Chien, Ting-//-Kuan, I. I.-//-Chern, Yijuang | The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions | review |
| Whatley, S. A.-//-Curti, D.-//-Das Gupta, F.-//-Ferrier, I. N.-//-Jones, S.-//-Taylor, C.-//-Marchbanks, R. M. | Superoxide, neuroleptics and the ubiquinone and cytochrome b5 reductases in brain and lymphocytes from normals and schizophrenic patients | preclinical |
| Whitehurst, T.-//-Howes, O. | The role of mitochondria in the pathophysiology of schizophrenia: A critical review of the evidence focusing on mitochondrial complex one | review |
| Wu, J.-//-Li, A.-//-Li, Y.-//-Li, X.-//-Zhang, Q.-//-Song, W.-//-Wang, Y.-//-Ogutu, J. O.-//-Wang, J.-//-Li, J.-//-Tang, R.-//-Zhang, F. | Chlorpromazine inhibits mitochondrial apoptotic pathway via increasing expression of tissue factor | preclinical |
| Xin, R.-//-Chen, Z.-//-Fu, J.-//-Shen, F.-//-Zhu, Q.-//-Huang, F. | Xanomeline Protects Cortical Cells From Oxygen-Glucose Deprivation via Inhibiting Oxidative Stress and Apoptosis | preclinical |
| Xuan, Y.-//-Yan, G.-//-Wu, R.-//-Huang, Q.-//-Li, X.-//-Xu, H. | The cuprizone-induced changes in (1)H-MRS metabolites and oxidative parameters in C57BL/6 mouse brain: Effects of quetiapine | preclinical |
| Yabuki, Y.-//-Wu, L.-//-Fukunaga, K. | Cognitive enhancer ST101 improves schizophrenia-like behaviors in neonatal ventral hippocampus-lesioned rats in association with improved CaMKII/PKC pathway | preclinical |
| Yang, M.-//-Wang, C.-//-Zhao, G.-//-Kong, D.-//-Liu, L.-//-Yuan, S.-//-Chen, W.-//-Feng, C.-//-Li, Z. | Comparative Analysis of the Pre- and Post-Medication Effects of Antipsychotic Agents on the Blood-Based Oxidative Stress Biomarkers in Patients with Schizophrenia: A Meta-Analysis | review |
| Zamani, E.-//-Ahmadi Shad, A.-//-Fatemi, H.-//-Mahboubi, S.-//-Motavallian, A.-//-Evazalipour, M. | Assessment of Protective Effects of Carvacrol on Haloperidol-Induced Oxidative Stress and Genotoxicity in Human Peripheral Blood Lymphocytes | clinical |
| Zerin Khan, Fatema-//-Sultana, Syeda Papia-//-Akhter, Nargis-//-Mosaddek, Abu Syed Md | Effect of Olanzapine and Risperidone on Oxidative Stress in Schizophrenia Patients %J International Biological and Biomedical Journal | clinical |
| Zhang, W. F.-//-Tan, Y. L.-//-Zhang, X. Y.-//-Chan, R. C.-//-Wu, H. R.-//-Zhou, D. F. | Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial | clinical |
| Zhang, X. Y.-//-Zhou, D. F.-//-Zhang, P. Y.-//-Wu, G. Y.-//-Su, J. M.-//-Cao, L. Y. | A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia | clinical |

| | | |
|---|---|---|
| Zhang, X. Y.-//-Zhou, D. F.-//-Cao, L. Y.-//-Zhang, P. Y.-//-Wu, G. Y.-//-Shen, Y. C. | The effect of risperidone treatment on superoxide dismutase in schizophrenia | clinical |
| Zhang, X. Y.-//-Zhou, D. F.-//-Cao, L. Y.-//-Xu, C. Q.-//-Chen, D. C.-//-Wu, G. Y. | The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial | clinical |